relation: http://publicatio.bibl.u-szeged.hu/35431/
title: Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023-2024 : EPICOVIDEHA-EPIFLUEHA Report
creator:  Salmanton-García Jon
creator:  Marchesi Francesco
creator:  Navrátil Milan
creator:  Piukovics Klára
creator:  Del Principe Maria Ilaria
creator:  Criscuolo Marianna
creator:  Bilgin Yavuz M
creator:  Fracchiolla Nicola S
creator:  Vena Antonio
creator:  Romano Alessandra
creator:  Falces-Romero Iker
creator:  Sgherza Nicola
creator:  Heras-Fernando Inmaculada
creator:  Biernat Monika M
creator:  Petzer Verena
creator:  Žák Pavel
creator:  Weinbergerová Barbora
creator:  Samarkos Michail
creator:  Erben Nurettin
creator:  van Praet Jens
creator:  López-García Alberto
creator:  Labrador Jorge
creator:  Lahmer Tobias
creator:  Drgoňa Ľuboš
creator:  Merelli Maria
creator:  Cuccaro Annarosa
creator:  Martín-Pérez Sonia
creator:  Dávila-Valls Julio
creator:  Farina Francesca
creator:  Cattaneo Chiara
subject: 03.03. Egészségtudományok
description: Community-acquired respiratory viral infections (CARV) significantly impact patients with hematological malignancies (HM), leading to high morbidity and mortality. However, large-scale, real-world data on CARV in these patients is limited. This study analyzed data from the EPICOVIDEHA-EPIFLUEHA registry, focusing on patients with HM diagnosed with CARV during the 2023-2024 autumn-winter season. The study assessed epidemiology, clinical characteristics, risk factors, and outcomes. The study examined 1312 patients with HM diagnosed with CARV during the 2023-2024 autumn-winter season. Of these, 59.5% required hospitalization, with 13.5% needing ICU admission. The overall mortality rate was 10.6%, varying by virus: parainfluenza (21.3%), influenza (8.8%), metapneumovirus (7.1%), RSV (5.9%), or SARS-CoV-2 (5.0%). Poor outcomes were significantly associated with smoking history, severe lymphopenia, secondary bacterial infections, and ICU admission. This study highlights the severe risk CARV poses to patients with HM, especially those undergoing active treatment. The high rates of hospitalization and mortality stress the need for better prevention, early diagnosis, and targeted therapies. Given the severe outcomes with certain viruses like parainfluenza, tailored strategies are crucial to improving patient outcomes in future CARV seasons.
date: 2024
type: Folyóiratcikk
type: PeerReviewed
format: text
identifier: http://publicatio.bibl.u-szeged.hu/35431/1/Salmanton-Garcia.pdf
identifier:     Salmanton-García Jon;  Marchesi Francesco;  Navrátil Milan;  Piukovics Klára;  Del Principe Maria Ilaria;  Criscuolo Marianna;  Bilgin Yavuz M;  Fracchiolla Nicola S;  Vena Antonio;  Romano Alessandra;  Falces-Romero Iker;  Sgherza Nicola;  Heras-Fernando Inmaculada;  Biernat Monika M;  Petzer Verena;  Žák Pavel;  Weinbergerová Barbora;  Samarkos Michail;  Erben Nurettin;  van Praet Jens;  López-García Alberto;  Labrador Jorge;  Lahmer Tobias;  Drgoňa Ľuboš;  Merelli Maria;  Cuccaro Annarosa;  Martín-Pérez Sonia;  Dávila-Valls Julio;  Farina Francesca;  Cattaneo Chiara: Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023-2024 : EPICOVIDEHA-EPIFLUEHA Report.   AMERICAN JOURNAL OF HEMATOLOGY.   ISSN 0361-8609 (2024)     
identifier: doi:10.1002/ajh.27565
relation: https://doi.org/10.1002/ajh.27565
relation: 35653108
language: eng
relation: info:eu-repo/semantics/altIdentifier/doi/10.1002/ajh.27565
rights: info:eu-repo/semantics/openAccess